Business
Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001
Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative partnership with TASK Clinical, a global contract research organization (CRO). Under the agreement, TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity — an exceptionally rare commitment that significantly de-risks development, enhances investor confidence, and strengthens the program
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"text","content":"Equity-backed commitment dramatically de-risks pivotal program, boosts licensing appeal, and strengthens commercialization readiness.","length":133,"tagName":"p"},{"type":"text","content":"HUNTINGTON, N.Y., Dec. 11, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative partnership with TASK Clinical, a global contract research organization (CRO). Under the agreement, TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity — an exceptionally rare commitment that significantly de-risks development, enhances investor confidence, and strengthens the program for global licensing opportunities.","length":583,"tagName":"p"},{"type":"text","content":"This milestone follows Sen-Jam's recent announcement appointing Rute Fernandes, a seasoned global life-sciences executive with leadership roles across Takeda, Shire, and Novartis, as Executive Advisor to accelerate commercialization pathways.","length":251,"tagName":"p"},{"type":"text","content":"A Synergistic Partnership Network: TASK Clinical + KVK Tech","length":59,"tagName":"p"},{"type":"text","content":"Sen-Jam now benefits from a vertically integrated development ecosystem:","length":72,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TASK Clinical providing clinical leadership and majority funding of Phase 3","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"KVK Tech, Sen-Jam's established corporate venture partner/CMO, driving formulation, CMC, and FDA submission readiness","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Rute Fernandes guiding global market expansion and commercialization strategy","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":273,"olType":false},{"type":"text","content":"KVK Tech has made significant progress in the formulation development and CMC work for SJP-001, including the manufacturing of GMP batches. Upon completion of the ongoing Phase 2 dose-ranging study, KVK Tech will finalize the FDA submission batches, enabling a rapid transition into Phase 3 and subsequent regulatory filing.","length":324,"tagName":"p"},{"type":"text","content":"This powerful alignment ensures Sen-Jam is de-risked acr...